Patents by Inventor Kishan Agarwala

Kishan Agarwala has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-PT217 TAU ANTIBODY
    Publication number: 20240076361
    Abstract: Disclosed herein an anti-pT217 Tau antibody or a pT217 Tau-binding fragment thereof.
    Type: Application
    Filed: February 17, 2022
    Publication date: March 7, 2024
    Inventors: Sonia CIEZAREK, Malcolm Ian ROBERTS, James Martin STADDON, Takashi OBARA, Yohei MUKAI, Lal Kishan AGARWALA
  • ANTI-TAU ANTIBODIES AND USES THEREOF
    Publication number: 20240034777
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Application
    Filed: January 4, 2023
    Publication date: February 1, 2024
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Anti-Tau antibodies and uses thereof
    Patent number: 11578120
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: February 14, 2023
    Assignees: Eisai R&D Management Co., Ltd., UCL Business LTD
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • ANTI-TAU ANTIBODIES AND USES THEREOF
    Publication number: 20210024622
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Application
    Filed: September 24, 2020
    Publication date: January 28, 2021
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Anti-tau antibodies and uses thereof
    Patent number: 10829547
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: November 10, 2020
    Assignees: Eisai R&D Management Co., Ltd., UCL Business LTD
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Anti-Tau antibodies and uses thereof
    Patent number: 10358485
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: July 23, 2019
    Assignees: Eisai R&D Management Co., Ltd., UCL Business PLC
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • ANTI-TAU ANTIBODIES AND USES THEREOF
    Publication number: 20190112365
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Application
    Filed: December 12, 2018
    Publication date: April 18, 2019
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • ANTI-TAU ANTIBODIES AND USES THEREOF
    Publication number: 20190112364
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Application
    Filed: October 16, 2018
    Publication date: April 18, 2019
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Anti human Notch4 antibody
    Patent number: 9969812
    Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: May 15, 2018
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino, Masahiko Katayama
  • Anti Human Notch4 Antibody
    Publication number: 20170096493
    Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 6, 2017
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino, Masahiko Katayama
  • Anti human Notch4 antibody
    Patent number: 9527921
    Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: December 27, 2016
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino, Masahiko Katayama
  • Anti Human Notch4 Antibody
    Publication number: 20160347858
    Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.
    Type: Application
    Filed: April 14, 2016
    Publication date: December 1, 2016
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino